Intrathecal administration bypasses the blood-brain barrier (BBB) by accessing the spinal canal directly. Our scientists apply this technique to effectively deliver both small and large molecules.
Oncotest’s presence in Freiburg, Germany enables Charles River to extend development and availability of our robust portfolio of syngeneic models to clients in Europe, providing further support to immuno-oncology researchers across the globe.
Charles River has joined the European Union Network of Laboratories for the Validation of Alternative Methods (EU-NETVAL).
We’ve recently added small animal imaging services at our Oncology Center of Excellence. This valuable tool enhances oncology research by allowing us to monitor molecular and cellular processes in live animals and perform quantitative, longitudinal analysis.
As Executive Director, Dr. Manja Bouman will ensure the business continues to deliver scientific excellence and superior client service.
WIL Research is a globally based contract research organization (CRO) with a mission to provide science applied in service to humanity.
Learn how we can help you target oncology from discovery to market with our recently expanded portfolio.
Nature spoke with Emily Hickey, Corporate Senior VP of Global Discovery, about our mission to deliver quality science to our partners while making the drug discovery ecosystem easier to navigate.
The growing interest in ion channel targets has driven a need for effective high-throughput screens. Here, our expert, Dr. Andrew Southan discusses the complex chemistry and biology applications involved in their development.
Dr. Maksym Kopanitsa has joined our CNS Center of Excellence, bringing expertise in electrophysiology and touchscreen testing to revolutionize how we measure cognitive function.